A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma

Abstract

Invasive breast cancer is a histologically heterogeneous disease; among numerous histological types, invasive ductal carcinoma (IDC) is the most common, present in 70%-75% of the cases (1, 2), followed by invasive lobular carcinoma (ILC), present in 5%-15% of the cases (1-3). Mixed invasive ductal and lobular carcinoma (IDLC), which has characteristics of both invasive ductal and lobular carcinoma, is present in approximately 5% of the cases (2). Lately, the prevalence of the lobular breast tumors has been on the rise, particularly in postmenopausal women; this increase has been linked with evidence suggesting that frequent use of hormone replacement therapy in recent years has increased the risk of ILC and IDLC development more than that of IDC (4-6). Clinicopathological characteristics and survival outcomes of ILC and IDC have been compared in numerous studies with conflicting results. On the other hand, few studies have compared IDLC with ILC and IDC. In this study, we compared ILC, IDC and IDLC in terms of clinicopathological and treatment features, metastatic patterns and longterm survival retrospectively in a 10 years patient cohort. Materials and Methods Ethical standards The research protocol of this clinical study was approved by the Ethics Committee of the

The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast

“…Many previous studies investigated the prognosis of IDC, ILC, and IDLC with inconsistent results [3-9, 11, 12, 15, 16]. Some found a similar prognosis between ILC and IDC [3,4,8,16], while others found that ILC showed better OS compared with IDC [6]. In the present study, there were no differences in BCSS between IDC and ILC in the multivariate model.…”

“…A recent study found that patients with IDLC had better disease-free survival and OS compared with ILC among postmenopausal women only with 204 cases of ILC and 258 cases of IDLC, while no survival differences were observed between IDLC and ILC in the total population [12]. Like many previous studies [9,11,16,20], the present study did not find any differences in BCSS and OS between IDLC and ILC before and after matching by the Kaplan-Meier curves. However, the subgroup analysis showed significant improvement in survival of ILC over IDLC in HR(+)HER2(+) and HR(−)HER2(−) subgroups.…”

“…The invasive lobular component of IDLC may be the result of direct clonal divergence from ductal to the lobular phenotypes in cases without LCIS, and is associated with aberrant expression of E-cadherin [10]. Some studies reported that there were no statistical differences in survival between IDLC and IDC or ILC of the breast [9,16,20]. Other studies found that patients with IDC had better disease-free survival and marginally better BCSS relative to those with IDLC [11].…”

Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features

“…Invasive lobular carcinoma (ILC) usually meets the definition of luminal A cancer, showing high ER and PR expression, with Ki-67 lower than 20%. Nevertheless, ILC long term prognosis does not differ from that of IBC of no special type 35 , 36 depending mostly on TNM staging at presentation 35 , 37 .…”

Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas

“…Although ER+ ILC and IDC tumors are treated clinically as a single disease (9), recent studies have established ER+ ILC as a distinct disease with unique sites of metastasis, frequent presentation of multifocal disease, delayed relapses, and decreased long-term survival compared to ER+ IDC tumors (10)(11)(12)(13)(14). Large-scale studies from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) have reported genomic and transcriptomic analyses on resected IDC and ILC tumors (15,16).…”